Veterans’ RightsAn independent resource for veterans
← All decisions
Granted

The Veteran's SCLE has required constant or near-constant systemic therapy, specifically Plaquenil, and the Board finds that he meets the criteria for a rating of 60 percent under DC 7806.

The deciding factor: Plaquenil is considered an immunosuppressive drug and the Veteran has been taking it nearly constantly since September 2004 in response to his SCLE rash.

Claimed conditions
Subacute cutaneous lupus erythematosus (SCLE)
How they argued it
Direct service connection
Exposure basis
None
Rating
Not verified here — check the original decision
Decision date
July 2, 2009
Citation
0924996

This is a plain-language summary generated by AI from a public Board of Veterans’ Appeals decision. It can contain errors — always verify against the original. Search VA.gov for the original decision (opens in a new tab) using citation 0924996.

What this means for you

A grant means the Board allowed the benefit or issue identified in this decision. Review the original order: other issues in the same appeal may have a different outcome, and this decision does not predict another claim.

What you can do next

Related decisions

Other Board decisions on a similar condition or argued the same way.

Free starter guide for your own claim

Reading this because you were denied or under-rated? Get the plain-English next steps — your appeal options, the deadline that protects you, and how appeals like yours turn out. One email, no spam.

We will only use this to send the guide. No spam, unsubscribe any time. We never sell your information.

We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.

This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.